Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Equity Income (2024)

Adial Pharmaceuticals' Equity Income history spans 1 years, with the latest figure at -$108817.0 for Q4 2024.

  • For Q4 2024, Equity Income changed N/A year-over-year to -$108817.0; the TTM value through Dec 2024 reached -$552182.0, changed N/A, while the annual FY2025 figure was -$492130.0, 10.88% up from the prior year.
  • Equity Income for Q4 2024 was -$108817.0 at Adial Pharmaceuticals, down from -$31023.0 in the prior quarter.
  • Across five years, Equity Income topped out at -$31023.0 in Q3 2024 and bottomed at -$222472.0 in Q2 2024.